O n Tuesday, Citi analysts boosted their price target on Akero Therapeutics (NASDAQ:AKRO) shares to $80 from the previous $65, while keeping a Buy rating on the stock. Currently trading at $51.71 ...

In other recent news, Akero Therapeutics has been the focus of several analyst upgrades following the release of positive 96-week SYMMETRY data. Canaccord Genuity raised its price target to $73 ...

Akero Therapeutics, 89bio, Boston Pharmaceuticals and more are working to bring novel treatment options for metabolic ...

Discover how Akero Therapeutics' EFX outshines competitors in MASH treatment, with groundbreaking results and strong ...

A drug developed by US biotech Akero Therapeutics has hit the mark in a phase 2b trial in non-alcoholic steatohepatitis (NASH) – catapulting it to the forefront of efforts to find effective ...

18.4% of Rezolute shares are held by insiders. Comparatively, 7.9% of Akero Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds ...

If you own Akero Therapeutics, Inc. ("Akero") (NASDAQ:AKRO), please contact Fletcher Moore by email at [email protected] or (212) 709-8245. You may be able to seek monetary damages ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Tuesday, shares of Akero Therapeutics Inc (Symbol: AKRO) entered into oversold territory, hitting an RSI ...

In a report released today, Eric Joseph from J.P. Morgan maintained a Hold rating on Verve Therapeutics (VERV – Research Report), with a price ...

Mark Iwicki, Chair of the Board of Akero Therapeutics. Arvind Kush, Chief Financial Officer and Chief Business Officer of Candid Therapeutics and former CFO of RayzeBio. Advancement of IkT-001 as ...

Akero Therapeutics, Inc. engages in the development of treatments for patients with serious metabolic diseases in the United States. The company’s lead product candidate is efruxifermin (EFX ...